DELCATH SYSTEMS, INC. (DCTH) Guidance & Earnings Results

On 2026-08-06 DELCATH SYSTEMS, INC. raised guidance: "Total HEPZATO KIT and CHEMOSAT revenue $104M-$108M (from prior range not specified, but implies…" — from its own filing, as read by EquiReason.

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

DCTHDELCATH SYSTEMS, INC.Follow DCTH — free

Medical Instruments & Supplies · Healthcare

—

Price chart with a free account

Market cap: 500.4M
P/E TTM: —
Dividend yield: —
52-week: —
Next earnings: 10 Nov, in 17 days

What management guided

each earnings 8-K · figures checked against the filing text

Release	Direction	What they said
6 Aug 26	Raised	Total HEPZATO KIT and CHEMOSAT revenue $104M-$108M (from prior range not specified, but implies increase) · full year
7 May 26	Raised	FY2026 total revenue at least $100M; gross margin 84%-87%; positive adjusted EBITDA. · full year
26 Feb 26	Raised	FY2026 total revenue at least $100M (vs FY2025 $85.2M); HEPZATO volume growth at least 20% (vs 140% in FY2025); gross margin 84-87% (vs 86% in FY2025) · full year
4 Nov 25	Raised	FY2025 total revenue raised to $83-85M (from prior undisclosed range); gross margins 85-87%; positive adjusted EBITDA and cashflow each quarter. · full year
20 Oct 25	Raised	FY2025 revenue guidance raised (specific numbers not provided in excerpt) · full year
6 Aug 25	Raised	FY2025 total CHEMOSAT and HEPZATO KIT revenue raised to $93-96M (increase of more than 150% over 2024); gross margins 83-85%; positive adjusted EBITDA and cashflow in each quarter of 2025 · full year

DELCATH SYSTEMS, INC. — questions

What guidance did DELCATH SYSTEMS, INC. give?: On 2026-08-06: "Total HEPZATO KIT and CHEMOSAT revenue $104M-$108M (from prior range not specified, but implies increase)"
When does DELCATH SYSTEMS, INC. report earnings?: DELCATH SYSTEMS, INC.'s next earnings report is expected on 2026-11-10.

Every figure on this page comes from DELCATH SYSTEMS, INC.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.

Important information. Figures on this page are taken from filings submitted to the U.S. Securities and Exchange Commission (SEC) and processed automatically by EquiReason. They may contain errors, omissions or delays, and EquiReason makes no representation or warranty as to their accuracy, completeness or timeliness. Always verify figures against the original filing on SEC EDGAR before relying on them.

This page is provided for general information and educational purposes only. It does not constitute investment, financial, legal or tax advice, and it is not a recommendation or an offer to buy, sell or hold any security. It does not take into account your objectives, financial situation or needs. Past performance does not guarantee future results; any reliance on this information is at your own risk. See our Disclaimer and Risk Disclosure.